Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > BUSINESS
BUSINESS
- PDUFA Date for Naldemedine Set for March 23, 2017
June 7, 2016
- Takecab Most Promoted Drug for 4 Months on End: Anterio
June 7, 2016
- FY2015 Earnings Roundup - 1: Operating Profits of Japan Makers Climb on Global Brands, Royalties
June 6, 2016
- Eisai, Novartis to Join Forces in US Lenvima Promotion for Kidney Cancer
June 6, 2016
- Astellas to Kick Off Global PIII on Xtandi for Triple-Negative Breast Cancer
June 6, 2016
- 27 Japan Drug Makers Derive Record 45.8% of Sales from Overseas Market: Jiho Tally
June 3, 2016
- AbbVie, EA Pharma Initiate Copromotion of Humira in GI Field
June 3, 2016
- Terano Tapped as President of Japan Vaccine
June 2, 2016
- Chugai Licenses Antibody SA237 to Roche, Japan Filing Slated for 2018
June 2, 2016
- Ex-Boehringer Japan Pres. Torii to Head Novartis Holdings Japan
June 2, 2016
- After Tax Hike Delay, Industry Officials Vigilant about Price Slash for Innovative Drugs
June 2, 2016
- Meiji Plans Japan-Bound Generic Projection in India to Seek Cost Competitiveness
June 1, 2016
- Meiji Seika Pharma Pins High Hopes on Schizophrenia Drug Sycrest
June 1, 2016
- Daiichi Sankyo Ceases Development of Patritumab for NSCLC
June 1, 2016
- Oncolys Concludes Option Agreement with US CRO for HIV Treatment Censavudine
June 1, 2016
- Takeda Consumer Healthcare Unit Aims for 100 Billion Yen Sales after Spin-Off
May 31, 2016
- Terumo Debuts Cell-Based Heart Failure Therapy HeartSheet
May 31, 2016
- Takeda’s Myeloma Drug Hopeful Ninlaro Rebuffed by CHMP
May 31, 2016
- Takeda Gets CHMP’s Positive Opinion for New Adcetris Indication
May 31, 2016
- Mylan Japan Labor Union, Management Reach Settlement; All 14 Members to Leave on May 31
May 30, 2016
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…